February 2017: Spironolactone - potion or poison?

In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the risk of hyperkalaemia associated with spironolactone in people with heart failure. They consider recent advice issued by the Medicines and Healthcare products Regulatory Agency and highlight the importance of regular monitoring of potassium and renal function. The editors also review the evidence for daclizumab, a drug for relapsing multiple sclerosis, and provide a brief introduction to the rationale and methods of qualitative research in health care.